A detailed history of Sei Investments CO transactions in Arvinas, Inc. stock. As of the latest transaction made, Sei Investments CO holds 26,594 shares of ARVN stock, worth $657,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,594
Previous 24,501 8.54%
Holding current value
$657,935
Previous $1.01 Million 30.07%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $51,194 - $84,557
2,093 Added 8.54%
26,594 $707,000
Q1 2024

May 07, 2024

BUY
$36.38 - $52.31 $612,311 - $880,429
16,831 Added 219.44%
24,501 $1.01 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $108,837 - $324,671
7,670 New
7,670 $315,000
Q2 2023

Aug 11, 2023

BUY
$21.73 - $31.43 $1,282 - $1,854
59 Added 0.6%
9,908 $245,000
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $257,551 - $366,973
9,849 New
9,849 $269,000
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $97,766 - $135,406
2,335 Added 15.97%
16,958 $755,000
Q2 2022

Aug 15, 2022

BUY
$36.01 - $74.24 $526,574 - $1.09 Million
14,623 New
14,623 $614,000
Q1 2022

May 13, 2022

SELL
$60.27 - $81.57 $326,181 - $441,456
-5,412 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $746,212 - $1.09 Million
-11,332 Reduced 67.68%
5,412 $441,000
Q3 2021

Nov 12, 2021

BUY
$73.2 - $107.87 $719,702 - $1.06 Million
9,832 Added 142.25%
16,744 $1.38 Million
Q2 2021

Aug 06, 2021

SELL
$60.45 - $84.26 $295,116 - $411,357
-4,882 Reduced 41.39%
6,912 $532,000
Q4 2020

Feb 08, 2021

BUY
$20.19 - $84.93 $238,120 - $1 Million
11,794 New
11,794 $1 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.32B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.